Cargando…
Development of a High-Efficacy Reprogramming Method for Generating Human Induced Pluripotent Stem (iPS) Cells from Pathologic and Senescent Somatic Cells
Induced pluripotent stem (iPS) cells are a type of artificial pluripotent stem cell induced by the epigenetic silencing of somatic cells by the Yamanaka factors. Advances in iPS cell reprogramming technology will allow aging or damaged cells to be replaced by a patient’s own rejuvenated cells. Howev...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7555779/ https://www.ncbi.nlm.nih.gov/pubmed/32942642 http://dx.doi.org/10.3390/ijms21186764 |
_version_ | 1783594087030456320 |
---|---|
author | Tanaka, Naomichi Kato, Hidemasa Tsuda, Hiromi Sato, Yasunori Muramatsu, Toshihiro Iguchi, Atsushi Nakajima, Hiroyuki Yoshitake, Akihiro Senbonmatsu, Takaaki |
author_facet | Tanaka, Naomichi Kato, Hidemasa Tsuda, Hiromi Sato, Yasunori Muramatsu, Toshihiro Iguchi, Atsushi Nakajima, Hiroyuki Yoshitake, Akihiro Senbonmatsu, Takaaki |
author_sort | Tanaka, Naomichi |
collection | PubMed |
description | Induced pluripotent stem (iPS) cells are a type of artificial pluripotent stem cell induced by the epigenetic silencing of somatic cells by the Yamanaka factors. Advances in iPS cell reprogramming technology will allow aging or damaged cells to be replaced by a patient’s own rejuvenated cells. However, tissue that is senescent or pathologic has a relatively low reprogramming efficiency as compared with juvenile or robust tissue, resulting in incomplete reprogramming; iPS cells generated from such tissue types do not have sufficient differentiation ability and are therefore difficult to apply clinically. Here, we develop a new reprogramming method and examine it using myofibroblasts, which are pathologic somatic cells, from patient skin tissue and from each of the four heart chambers of a recipient heart in heart transplant surgery. By adjusting the type and amount of vectors containing transcriptional factors for iPS cell reprogramming, as well as adjusting the transfection load and culture medium, the efficiency of iPS cell induction from aged patient skin-derived fibroblasts was increased, and we successfully induced iPS cells from myocardial fibroblasts isolated from the pathologic heart of a heart transplant recipient. |
format | Online Article Text |
id | pubmed-7555779 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-75557792020-10-19 Development of a High-Efficacy Reprogramming Method for Generating Human Induced Pluripotent Stem (iPS) Cells from Pathologic and Senescent Somatic Cells Tanaka, Naomichi Kato, Hidemasa Tsuda, Hiromi Sato, Yasunori Muramatsu, Toshihiro Iguchi, Atsushi Nakajima, Hiroyuki Yoshitake, Akihiro Senbonmatsu, Takaaki Int J Mol Sci Article Induced pluripotent stem (iPS) cells are a type of artificial pluripotent stem cell induced by the epigenetic silencing of somatic cells by the Yamanaka factors. Advances in iPS cell reprogramming technology will allow aging or damaged cells to be replaced by a patient’s own rejuvenated cells. However, tissue that is senescent or pathologic has a relatively low reprogramming efficiency as compared with juvenile or robust tissue, resulting in incomplete reprogramming; iPS cells generated from such tissue types do not have sufficient differentiation ability and are therefore difficult to apply clinically. Here, we develop a new reprogramming method and examine it using myofibroblasts, which are pathologic somatic cells, from patient skin tissue and from each of the four heart chambers of a recipient heart in heart transplant surgery. By adjusting the type and amount of vectors containing transcriptional factors for iPS cell reprogramming, as well as adjusting the transfection load and culture medium, the efficiency of iPS cell induction from aged patient skin-derived fibroblasts was increased, and we successfully induced iPS cells from myocardial fibroblasts isolated from the pathologic heart of a heart transplant recipient. MDPI 2020-09-15 /pmc/articles/PMC7555779/ /pubmed/32942642 http://dx.doi.org/10.3390/ijms21186764 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Tanaka, Naomichi Kato, Hidemasa Tsuda, Hiromi Sato, Yasunori Muramatsu, Toshihiro Iguchi, Atsushi Nakajima, Hiroyuki Yoshitake, Akihiro Senbonmatsu, Takaaki Development of a High-Efficacy Reprogramming Method for Generating Human Induced Pluripotent Stem (iPS) Cells from Pathologic and Senescent Somatic Cells |
title | Development of a High-Efficacy Reprogramming Method for Generating Human Induced Pluripotent Stem (iPS) Cells from Pathologic and Senescent Somatic Cells |
title_full | Development of a High-Efficacy Reprogramming Method for Generating Human Induced Pluripotent Stem (iPS) Cells from Pathologic and Senescent Somatic Cells |
title_fullStr | Development of a High-Efficacy Reprogramming Method for Generating Human Induced Pluripotent Stem (iPS) Cells from Pathologic and Senescent Somatic Cells |
title_full_unstemmed | Development of a High-Efficacy Reprogramming Method for Generating Human Induced Pluripotent Stem (iPS) Cells from Pathologic and Senescent Somatic Cells |
title_short | Development of a High-Efficacy Reprogramming Method for Generating Human Induced Pluripotent Stem (iPS) Cells from Pathologic and Senescent Somatic Cells |
title_sort | development of a high-efficacy reprogramming method for generating human induced pluripotent stem (ips) cells from pathologic and senescent somatic cells |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7555779/ https://www.ncbi.nlm.nih.gov/pubmed/32942642 http://dx.doi.org/10.3390/ijms21186764 |
work_keys_str_mv | AT tanakanaomichi developmentofahighefficacyreprogrammingmethodforgeneratinghumaninducedpluripotentstemipscellsfrompathologicandsenescentsomaticcells AT katohidemasa developmentofahighefficacyreprogrammingmethodforgeneratinghumaninducedpluripotentstemipscellsfrompathologicandsenescentsomaticcells AT tsudahiromi developmentofahighefficacyreprogrammingmethodforgeneratinghumaninducedpluripotentstemipscellsfrompathologicandsenescentsomaticcells AT satoyasunori developmentofahighefficacyreprogrammingmethodforgeneratinghumaninducedpluripotentstemipscellsfrompathologicandsenescentsomaticcells AT muramatsutoshihiro developmentofahighefficacyreprogrammingmethodforgeneratinghumaninducedpluripotentstemipscellsfrompathologicandsenescentsomaticcells AT iguchiatsushi developmentofahighefficacyreprogrammingmethodforgeneratinghumaninducedpluripotentstemipscellsfrompathologicandsenescentsomaticcells AT nakajimahiroyuki developmentofahighefficacyreprogrammingmethodforgeneratinghumaninducedpluripotentstemipscellsfrompathologicandsenescentsomaticcells AT yoshitakeakihiro developmentofahighefficacyreprogrammingmethodforgeneratinghumaninducedpluripotentstemipscellsfrompathologicandsenescentsomaticcells AT senbonmatsutakaaki developmentofahighefficacyreprogrammingmethodforgeneratinghumaninducedpluripotentstemipscellsfrompathologicandsenescentsomaticcells |